Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5202-5208

  Sangawa, Hidehiro ^a   Komeno, Takashi ^a   Nishikawa, Hiroshi ^a   Yoshida, Atsushi ^a   Takahashi, Kazumi ^a   Nomura, Nobuhiko ^a   Furuta, Yousuke ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIVIRUS AGENT; CELL ENZYME; CYTIDINE TRIPHOSPHATE; GUANOSINE TRIPHOSPHATE; NUCLEOSIDE TRIPHOSPHATE; PHOSPHORUS 32; RNA DIRECTED RNA POLYMERASE INHIBITOR; T 705 4 RIBOFURANOSYL 5 TRIPHOSPHATE; T 705RTP; UNCLASSIFIED DRUG; URIDINE TRIPHOSPHATE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME KINETICS; INFLUENZA VIRUS; KINETICS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RNA VIRUS;

ADENOSINE TRIPHOSPHATE; AMIDES; ANIMALS; ANTIVIRAL AGENTS; BINDING, COMPETITIVE; CYTIDINE TRIPHOSPHATE; DOGS; ENZYME ASSAYS; GUANOSINE TRIPHOSPHATE; INFLUENZA A VIRUS, H1N1 SUBTYPE; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; PROTEIN BINDING; PYRAZINES; RNA REPLICASE; RNA, VIRAL; URIDINE TRIPHOSPHATE; VIRAL PROTEINS;

EID: 84885907998     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00649-13     Document Type: Article

References (25)

1. von Itzstein M. 2007. The war against influenza: Discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6:967-974.
2. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
3. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. 2003. High frequency of resistant viruses harboring different mutations in amantadine-Treated children with influenza. J. Infect. Dis. 188:57-61.
4. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981.
5. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
6. Takahashi K, Furuta Y, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Shiraki K. 2003. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14:235-241.
7. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antivir. Res. 82:95-102.
8. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168-3176.
9. Julander JG, Shafer K, Smee DF, Morrey JD, Furuta Y. 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53:202-209.
10. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. 2010. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother. 55:782-787.
11. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, Christensen AJ, Furuta Y. 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antivir. Res. 80:377-379.
12. Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y. 2010. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 54:126-133.
13. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF. 2012. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antivir. Res. 94:103-110.
14. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 107:882-887.
15. Hay AJ, Skehel JJ, McCauley J. 1982. Characterization of influenza virus RNA complete transcripts. Virology 116:517-522.
16. Hagen M, Chung TD, Butcher JA, Krystal M. 1994. Recombinant influenza virus polymerase: Requirement of both 5= and 3= viral ends for endonuclease activity. J. Virol. 68:1509-1515.
17. Chung TD, Cianci C, Hagen M, Terry B, Matthews JT, Krystal M, Colonno RJ. 1994. Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 91:2372-2376.
18. Ishihama A, Mizumoto K, Kawakami K, Kato A, Honda A. 1986. Proofreading function associated with the RNA-dependent RNA polymerase from influenza virus. J. Biol. Chem. 261:10417-10421.
19. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. 1995. Inhibition of influenza virus transcription by 2=-deoxy-2=-fluoroguanosine. Antimicrob. Agents Chemother. 39:2454-2458.
20. Ilsley DD, Lee SH, Miller WH, Kuchta RD. 1995. Acyclic guanosine analogs inhibit DNA polymerases and with very different potencies and have unique mechanisms of action. Biochemistry 34:2504-2510.
21. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6:1375-1379.
22. Deval J. 2009. Antimicrobial strategies: Inhibition of viral polymerases by 3=-hydroxyl nucleosides. Drugs 69:151-166.
23. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: Lethal mutagenesis? J. Mol. Med. 80:86-95.
24. Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87:3741-3751.
25. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52:1604-1612.